{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:43:11Z","timestamp":1789911791424,"version":"4.0.1"},"reference-count":23,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T00:00:00Z","timestamp":1326153600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> About half of the patients with chronic hepatitis C are still not cured by treatment with the current standard of care, peginterferon \u03b1\/ribavirin. Direct antiviral drugs may overcome the limitations of standard antiviral therapy. The most promising new agents are inhibitors of the NS3\/4A protease, the NS5B polymerase and the NS5A protein. Several compounds against these targets have entered clinical evaluation. Early clinical trials have emphasized the high potential for selecting resistant Hepatitis C virus variants. Furthermore, development of several new direct antivirals was stopped because of concerns over tolerability and safety. Then, in 2010, two phase III trials with the NS3\/4A protease inhibitors boceprevir (SPRINT\u20102) and telaprevir (ADVANCE) showed that the combination of these compounds with standard care increases sustained virologic response rates in treatment\u2010na\u00efve genotype 1 patients from 38\u201344% to 66\u201375%. Future goals of therapy with direct antiviral agents are to improve tolerability, shorten the duration of therapy and overcome the issue of resistance. Several studies have been initiated that combine different novel therapies, with and without interferon \u03b1\/ribavirin.<\/jats:p>","DOI":"10.1111\/j.1365-2893.2011.01526.x","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T02:59:57Z","timestamp":1326250797000},"page":"48-51","source":"Crossref","is-referenced-by-count":32,"title":["New developments in HCV therapy"],"prefix":"10.1111","volume":"19","author":[{"given":"B.","family":"Kronenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,10]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"JacobsonM McHutchisonJ DusheikoGet\u00a0al.Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment\u2010na\u00efve patients: final results of phase 3 ADVANCE study. AASLD2010; Abstract #211."},{"key":"e_1_2_7_3_2","unstructured":"KiefferT BartelsD SullivanJet\u00a0al.Clinical virology results from telaprevir phase 3 study ADVANCE. AASLD2010; LB\u201011."},{"key":"e_1_2_7_4_2","unstructured":"ShermanK FlammS AfdhalNet\u00a0al.Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48\u2003weeks in treatment\u2010na\u00efve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. AASLD2010; LB\u20102."},{"key":"e_1_2_7_5_2","unstructured":"Telaprevir phase 3 trial fact sheet. Available at:http:\/\/wwwvrtxcom\/current\u2010projects\/drug\u2010candidates\/telaprevir\u2010VX\u2010950html; 2010 (accessed 31 May 2010)."},{"key":"e_1_2_7_6_2","unstructured":"BronowickiJ McConeJ BaconBet\u00a0al.Response\u2010guided therapy (RGT) with boceprevir (BOC)\u2003+\u2003peginterferon alfa\u20102b\/ribavirin (P\/R) for treatment\u2010na\u00efve patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48\u2010wk fixed\u2010duration regimen with BOC\u2003+\u2003P\/R in SPRINT\u20102. AASLD2010; LB15."},{"key":"e_1_2_7_7_2","unstructured":"PoordadF McConeJ BaconBet\u00a0al.Boceprevir (BOC) combined with peginterferon alfa\u20102b\/ribavirin (P\/R) for treatment\u2010na\u00efve patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT\u20102 final results. AASLD2010; #LB4."},{"key":"e_1_2_7_8_2","unstructured":"BaconBR GordonSC LawitzEet\u00a0al.HCV RESPOND\u20102 final results: high sustained virologic response among genotype 1 previous non\u2010responders and relapsers to peginterferon\/ribavirin when re\u2010treated with boceprevir plus PEGINTRON (peginterferon alfa\u20102b)\/ribavirin. AASLD2010; #216."},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(10)60059-1"},{"key":"e_1_2_7_10_2","doi-asserted-by":"crossref","unstructured":"BenhamouY MoussalliJ RatziuVet\u00a0al.Activity of telaprevir monotherapy or in combination with peginterferon\u2010alfa\u20102a and ribavirin in treatment\u2010na\u00efve genotype 4 hepatitis\u2010C patients: final results of study C210. AASLD2010; #828.","DOI":"10.1016\/S0168-8278(09)60012-X"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.11.055"},{"key":"e_1_2_7_12_2","unstructured":"HuangM PodosS PatelDet\u00a0al.ACH\u20102684: HCV NS3 protease inhibitor with potent activity against multiple genotypes and known resistant variants. AASLD2010; #1859."},{"key":"e_1_2_7_13_2","unstructured":"BrainardDM PetryA Van DyckKet\u00a0al.Safety and antiviral activity of MK\u20105172 a novel HCV NS3\/4a protease inhibitor with potent activity against known resistance mutants in genotype 1 and 3 HCV\u2010infected patients. AASLD2010; #807."},{"key":"e_1_2_7_14_2","unstructured":"BrownN VigP RubyEet\u00a0al.Safety and pharmacokinetics of PPI\u2010461 a potent new hepatitis C virus NS5A inhibitor with pan\u2010genotype activity. AASLD2010; LB\u201012."},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.449"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08463"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.013"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","unstructured":"MuirA LawitzE Rodriguez\u2010TorresMet\u00a0al.IL28B polymorphism and kinetics of antiviral activity for ANA598 in combination with pegylated interferon alfa2\u2010a plus ribavirin in treatment naive genotype 1 chronic HCV patients. AASLD2010; #1852.","DOI":"10.1016\/S0168-8278(10)61200-7"},{"key":"e_1_2_7_20_2","doi-asserted-by":"crossref","unstructured":"ThompsonA MuirA SulkowskiMet\u00a0al.Hepatitis C trials that combine investigational agents with pegylated interferon alfa should be stratified by IL28B genotype. AASLD2010; #810.","DOI":"10.1002\/hep.23826"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(10)60751-9"},{"key":"e_1_2_7_22_2","unstructured":"ZeuzemS AsselahT AngusPWet\u00a0al.Strong antiviral activity and safety of IFN sparing treatment with the protease inhibitor BI 201335 the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. AASLD2010; LB\u20107."},{"key":"e_1_2_7_23_2","unstructured":"MoH KuKS YangHet\u00a0al.Enhancedin vitroantiviral activity by combining GS\u20109256 a novel protease inhibitor with GS\u20109190 a non\u2010nucleoside NS5B inhibitor. AASLD2010; #1867."},{"key":"e_1_2_7_24_2","unstructured":"LokAS GardinerDF LawitzEet\u00a0al.Combination therapy with BMS\u2010790052 and BMS\u2010650032 alone or with Peginterferon\/ribavirin results in undetectable HCV RNA through 12\u2003weeks of therapy in HCV genotype 1 null responders. AASLD2010; LB\u20108."}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2011.01526.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2011.01526.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T19:33:51Z","timestamp":1694460831000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2011.01526.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":23,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1111\/j.1365-2893.2011.01526.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2011.01526.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}